Search Results
Feb 23, 2026, 18:01 ET L'UEG appelle les décideurs politiques de l'UE à donner la priorité à la santé digestive dans le CFP 2028-2034 et le 10e PC pour renforcer la compétitivité de l'Europe
une priorité explicite dans le prochain budget à long terme de l'UE. L'investissement prévu à l'adressedans le cadre du 10e PC et du programme EU4Health pour la période postérieure à 2027 est essentiel pour favoriser la prévention, renforcer la résilience des systèmes de santé et traduire la recherche
More news about: United European Gastroenterology
Feb 23, 2026, 18:01 ET La UEG insta a los responsables políticos de la UE a priorizar la salud digestiva en el MFP 2028-2034
justifican una priorización explícita en el próximo presupuesto a largo plazo de la UE. La inversión específica a través del 10º Programa Marco y el programa EU4Health posterior a 2027 es fundamental para impulsar la prevención, fortalecer la resiliencia del sistema sanitario y traducir la investigación en resultados
More news about: United European Gastroenterology
Feb 23, 2026, 17:31 ET Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
More news about: DelveInsight Business Research, LLP
Feb 23, 2026, 16:05 ET BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
study in achondroplasia 1H'26PALYNZIQ:U.S. PDUFA date for the adolescent label expansion February 28, 2026; EU approval 2026BMN 401:Phase 3 topline data in 1 to 12 year-old population with ENPP1 deficiency 1H'26; global
More news about: BioMarin Pharmaceutical Inc.
Feb 23, 2026, 15:37 ET Notification de transactions par une personne exerçant des responsabilités managériales conformément à l'article 19 du règlement (UE) n° 596/2014 relatif aux abus de marché
George, membre de son conseil d'administration et directeur général, conformément à l'article 19 du règlement (UE) n° 596/2014 sur les abus de marché (EU MAR).
More news about: SWI Group
Feb 23, 2026, 15:32 ET Notificación de transacción de conformidad con el artículo 19 del Reglamento sobre Abuso de Mercado (UE)
miembro de su consejo de administración y consejero delegado, de conformidad con el artículo 19 del Reglamento sobre Abuso de Mercado (UE) No. 596/2014 (EU MAR).
More news about: SWI Group
Feb 23, 2026, 14:42 ET Zentiva požaduje zastavenie platnosti smernice o čistení komunálnych odpadových vôd na úrovni EÚ s cieľom chrániť dostupnosť liekov
16 členskými štátmi EÚ, spoločnosť Zentiva v roku 2025 podala žalobu na zrušenie smernice s cieľom zabezpečiť bezpečné dodávky základných liekov pre pacientov, ktorí sú od nich denne závislí.Nedávne rozhodnutie objasňuje, ako Súdny dvor vykladá pojem právna legitimácia podľa práva EÚ. Dospelo sa k záveru,
More news about: Zentiva
Feb 23, 2026, 14:12 ET Notification of Transaction by Person Discharging Managerial Responsibilities pursuant to Article 19 of the Market Abuse Regulation (EU) No 596/2014
Max-Hervé George, a member of its board of directors and Chief Executive Officer, in accordance with Article 19 of the Market Abuse Regulation (EU) No. 596/2014 (EU MAR).
More news about: SWI Group
Feb 23, 2026, 14:06 ET Notification of Transaction by Person Discharging Managerial Responsibilities pursuant to Article 19 of the Market Abuse Regulation (EU) No 596/2014
Max-Hervé George, a member of its board of directors and Chief Executive Officer, in accordance with Article 19 of the Market Abuse Regulation (EU) No. 596/2014 (EU MAR).
More news about: SWI Group
Feb 23, 2026, 12:00 ET New Gentle Methyl Conversion Kit Delivers High-Accuracy Profiling from as Little as 100 pg of DNA
https://ellisbio.com/supermethyl-max-bisulfite-conversion-kit/). Ellis Bio has distributor partners internationally, including PELOBiotech (EU), Stratech Scientific (UK), Eagle Biosciences (US), and AS ONE (Japan). About Ellis Bio Ellis Bio, Inc. is developing multi-omic tools
More news about: Ellis Bio Inc
Feb 23, 2026, 10:00 ET HOUSE OF ROSE PROFESSIONAL ANNOUNCES 2026 BREAK THE CEILING TOUCH THE SKY® 101 BEST GLOBAL COMPANIES FOR WOMEN IN LEADERSHIP INDEX (BTC 101 GLOBAL INDEX)
summit is supported by several major chambers of commerce internationally including AmCham, BritCham, Singapore International Chamber of Commerce (SICC), EU-ASEAN Business Council, EuroCham, French Chamber, Canadian Chamber, etc. The world's most successful companies including DFI Retail Group, Reckitt,
More news about: House of Rose Professional Pte. Ltd.
Feb 23, 2026, 09:00 ET /R E P E A T -- Claigan Webinar - A Practical Walkthrough of an EU MDR Justification Document/
justified under section 10.4 of the EU Medical Device Regulation (EU MDR).With the addition of cobalt and NMP to the CMR list, the majority of invasive, fluid, or gas path medical devices are now requiring justification documents for compliance to EU MDR.Example affected products
More news about: Claigan Environmental Inc.
Feb 23, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Công Bố Nắm Giữ Tới 4,423 Triệu Token ETH và Tổng Cộng 9,6 Tỷ USD Tiền Mã Hóa và Tiền Mặt
content:https://www.prnewswire.com/vn/news-releases/u0062u0069u0074u006Du0069u006Eu0065u002Du0069u006Du006Du0065u0072u0073u0069u006Fu006Eu002Du0074u0065u0063u0068u006Eu006Fu006Cu006Fu0067u0069-302694501.htmlSOURCE
More news about: Bitmine Immersion Technologies, Inc.
Feb 23, 2026, 08:18 ET The Province of Entre Ríos announces the commencement of Offer to Purchase for Cash its U.S. Dollar Step Up Notes due 2028
Economic Area and the United Kingdom, this communication is only addressed to and directed at qualified investors in that Member State within the meaning of Regulation (EU) 2017/1129.This announcement is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of Section
More news about: The Province of Entre Ríos
Feb 23, 2026, 08:14 ET PAN GLOBAL INICIA EL PROGRAMA DE SONDEOS 2026 EN EL PROYECTO ESCACENA, ESPAÑA
TSXV: PGZ | OTCQB: PGZFF | FRA: 2EU El Pozo objetivo VMS de gran tamaño con alta certidumbreAnomalías de cobre en suelos que se extienden a lo largo de 1,6 km en dirección este-oesteAnomalías geoquímicas y geofísicas coincidentes
More news about: Pan Global Resources Inc.
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
multimedia:https://www.prnewswire.com/news-releases/genprex-strengthens-intellectual-property-portfolio-with-japanese-and-eu-patents-for-reqorsa-gene-therapy-in-combination-with-immunotherapies-to-treat-cancer-302694069.htmlSOURCE
More news about: Genprex, Inc.
Feb 23, 2026, 07:27 ET PAN GLOBAL COMMENCES 2026 DRILL PROGRAM AT ESCACENA PROJECT, SPAIN
PGZFF | FRA: 2EU El Pozo is a large scale, high-confidence VMS targetSoil copper anomaly trends over 1.6 km east-westCoincident
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:27 ET PAN GLOBAL BEGINNT BOHRPROGRAMM 2026 IM PROJEKT ESCACENA, SPANIEN
PGZFF | FRA: 2EU El Pozo ist ein großflächiges, vielversprechendes VMS-ZielgebietTrends der Kupferanomalien im Boden
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:27 ET PAN GLOBAL COMMENCES 2026 DRILL PROGRAM AT ESCACENA PROJECT, SPAIN
PGZFF | FRA: 2EU El Pozo is a large scale, high-confidence VMS targetSoil copper anomaly trends over 1.6 km east-westCoincident
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:27 ET PAN GLOBAL LANCE LE PROGRAMME DE FORAGE 2026 SUR LE PROJET ESCACENA, EN ESPAGNE
PGZFF | FRA : 2EU El Pozo est une cible VMS à grande échelle et à haut degré de certitude.Tendances de l'anomalie de
More news about: Pan Global Resources Inc.
Feb 23, 2026, 07:00 ET FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants
Gadopiclenol was first approved by the FDA in September 2022 and obtained EU approval in December 2023 for use in adult patients and in pediatric patients aged 2 years and older.10,11 In January 2026, gadopiclenol received EU approval expanding its approved indications to include neonates and infants.11Please
More news about: Bracco Group
Feb 23, 2026, 06:32 ET Akums Strengthens European and UK Presence -- India's Largest CDMO Expands Global Footprint
Akums Drugs & Pharmaceuticals Ltd., India's largest CDMO, has secured European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities located in India, reinforcing its growing presence in regulated global markets.
More news about: Akums Drugs & Pharmaceuticals Ltd
Feb 23, 2026, 06:29 ET Akums Strengthens European and UK Presence -- India's Largest CDMO Expands Global Footprint
Akums Drugs & Pharmaceuticals Ltd., India's largest CDMO, has secured European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities located in India, reinforcing its growing presence in regulated global markets.
More news about: Akums Drugs & Pharmaceuticals Ltd
Feb 23, 2026, 06:04 ET Zentiva Demands EU-Level Stop-the-Clock on the UWWTD to Protect Medicine Availability
raised by 16 EU Member States, in 2025 Zentiva filed a legal action to request annulment of the Directive to safeguard the secure supply of essential medicines for the patients who depend on them every day.The recent decision clarifies how the Court interprets legal standing under EU law. It concludes
More news about: Zentiva
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
platinum-based chemoradiotherapy (CRT). Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, "Since its initial EU approval in July 2024, sugemalimab has become one of only two PD-(L)1 antibodies approved for stage III NSCLC in Europe, providing a comprehensive treatment
More news about: CStone Pharmaceuticals